{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:04:57Z","timestamp":1790697897910,"version":"4.1.0"},"reference-count":56,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T00:00:00Z","timestamp":1754870400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of VitreoRetinal Diseases"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:p>\n                    <jats:bold>Purpose:<\/jats:bold>\n                    To compare the incremental cost-effectiveness of a clinical trial-simulated step-therapy versus real-world treatment for diabetic macular edema (DME).\n                    <jats:bold>Methods:<\/jats:bold>\n                    A theoretical Markov model (follow-up of 2 years and lifetime of 17 years) from the 2025 US societal perspective was used to compare the costs and cost-effectiveness between bevacizumab-first (Protocol AC) and real-world regimens from the Vestrum Health database. The modeling used mean characteristics from a reference case and analyzed low- and high-cost scenarios, total societal costs from formal and informal healthcare and non-healthcare sectors, and differences in utility (visual acuity outcomes) between arms.\n                    <jats:bold>Results:<\/jats:bold>\n                    Protocol AC bevacizumab-first in the reference case was 14% more expensive at 2 years, with a total adjusted societal cost of $69 850 versus $61 304 for real-world treatment. Although visual acuity gains were higher with Protocol AC, the incremental cost-utility ratio (ICUR) was $105 335\/quality-adjusted life years (QALY) at 2 years and $151 032\/QALY over 17 years, higher than most societal willingness-to-pay thresholds. In the low-cost scenario, Protocol AC was neither cost-saving nor cost-effective at 2 years (ICUR $82 283\/QALY) but was cost-effective over 17 years (ICUR $591\/QALY). In the high-cost scenario, Protocol AC was not cost-effective at 2 years (ICUR $219 420\/QALY) or 17 years (ICUR $207 589\/QALY). Probability sensitivity analysis showed that Protocol AC was more expensive in 87% of modeled scenarios and not cost-effective in 76%.\n                    <jats:bold>Conclusions:<\/jats:bold>\n                    Compared with real-world treatment, protocol AC bevacizumab-first treatment for DME was generally not cost-saving. Although better vision outcomes were achieved with bevacizumab-first, the protocol was generally not cost-effective due to greater treatment burdens.\n                  <\/jats:p>","DOI":"10.1177\/24741264251359888","type":"journal-article","created":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T11:05:01Z","timestamp":1754910301000},"page":"555-565","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":2,"title":["Cost-Effectiveness of Treatments for Diabetic Macular Edema: Simulated Bevacizumab-First Step Therapy Versus Real-World Practice"],"prefix":"10.1177","volume":"9","author":[{"given":"Ella H.","family":"Leung","sequence":"first","affiliation":[{"name":"Georgia Retina, Atlanta, GA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2229-5343","authenticated-orcid":false,"given":"Dilraj S.","family":"Grewal","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Duke University School of Medicine, Durham, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuel","family":"Gerbi","sequence":"additional","affiliation":[{"name":"Department of Genetics, Washington University, St. Louis, MO, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9522-8486","authenticated-orcid":false,"given":"Miguel","family":"Busquets","sequence":"additional","affiliation":[{"name":"Retina Associates of Kentucky, EyeCare Partners, Lexington, KY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Niles","sequence":"additional","affiliation":[{"name":"Buffalo Niagara Retina Associates, Buffalo, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2055-9453","authenticated-orcid":false,"given":"Dan A.","family":"Gong","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Massachusetts Eye and Ear, Harvard Medical School, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton M.","family":"Kolomeyer","sequence":"additional","affiliation":[{"name":"NJRetina, Teaneck, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitika","family":"Aggarwal","sequence":"additional","affiliation":[{"name":"Vestrum Health, Naperville, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Boucher","sequence":"additional","affiliation":[{"name":"Vestrum Health, Naperville, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill","family":"Blim","sequence":"additional","affiliation":[{"name":"American Society of Retina Specialists, Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reginald","family":"Sanders","sequence":"additional","affiliation":[{"name":"The Retina Group of Washington, Chevy Chase, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6574-388X","authenticated-orcid":false,"given":"Paul","family":"Hahn","sequence":"additional","affiliation":[{"name":"NJRetina, Teaneck, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,8,11]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2022.0052"},{"key":"e_1_3_3_3_2","unstructured":"US Food and Drug Administration. Pacifico National Inc. dba AmEx pharmacy issues voluntary nationwide recall for all Lots of Bevacizumab. October 8 2020. Accessed January 6 2024. https:\/\/www.fda.gov\/safety\/recalls-market-withdrawals-safety-alerts\/pacifico-national-inc-dba-amex-pharmacy-issues-voluntary-nationwide-recall-all-lots-bevacizumab"},{"key":"e_1_3_3_4_2","unstructured":"US Food and Drug Administration. AmEx pharmacy issues voluntary nationwide recall for one Lot of Bevacizumab 1.25mg\/0.05mL 31 G syringe due to reported defective delivery system. June 3 2019. Accessed January 6 2024. https:\/\/www.fda.gov\/safety\/recalls-market-withdrawals-safety-alerts\/amex-pharmacy-issues-voluntary-nationwide-recall-one-lot-bevacizumab-125mg005ml-31-g-syringe-due"},{"key":"e_1_3_3_5_2","unstructured":"Pine Pharmaceuticals announces voluntary recalls including Avastin. The American Society of Retina Specialists. October 2 2023. Accessed January 6 2024. https:\/\/www.asrs.org\/clinical\/clinical-updates\/9342\/Pine-Pharmaceuticals-Announces-Voluntary-Recalls-Including-Avastin"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1097\/ICB.0000000000000570"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajoc.2017.07.009"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2016.02.022"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1414264"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.7326\/M13-0768"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2204225"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2022.6142"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2022.11.010"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2013.01.068"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1177\/24741264241275283"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.12195"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.3390\/healthcare9101309"},{"key":"e_1_3_3_18_2","unstructured":"National Academies of Sciences Engineering and Medicine; Division of Behavioral and Social Sciences and Education; Committee on National Statistics et al. The emerging older workforce. In: Understanding the Aging Workforce: Defining a Research Agenda. National Academies Press (US); 2022. Accessed December 12 2023. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK588545\/"},{"key":"e_1_3_3_19_2","unstructured":"Private industry workers with sick leave benefits received 8 days per year at 20 years of service. The Economics Daily. US Bureau of Labor Statistics. March 8 2019. Accessed December 6 2023. https:\/\/www.bls.gov\/opub\/ted\/2019\/private-industry-workers-with-sick-leave-benefits-received-8-days-per-year-at-20-years-of-service.htm"},{"key":"e_1_3_3_20_2","unstructured":"Van Rossum G Drake F. Python 3 reference manual. CreateSpace; 2009."},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.3928\/23258160-20140306-08"},{"key":"e_1_3_3_22_2","unstructured":"Centers for Medicare and Medicaid Services. ASC payment rates \u2013 Addenda. 2025. Accessed March 6 2025. https:\/\/www.cms.gov\/medicare\/payment\/prospective-payment-systems\/ambulatory-surgical-center-asc\/asc-payment-rates-addenda"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-0354"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2023.03.492"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2023.10.010"},{"key":"e_1_3_3_26_2","unstructured":"BLS. Unpaid eldercare in the United States - 2021-2022. 2023. Accessed December 12 2023. https:\/\/www.bls.gov\/news.release\/pdf\/elcare.pdf"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000000164"},{"key":"e_1_3_3_28_2","unstructured":"Social Security Administration. Retirement benefits. 2025. https:\/\/www.ssa.gov\/pubs\/EN-05-10035.pdf"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2021.100852"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-014-0132-3"},{"key":"e_1_3_3_31_2","unstructured":"World Health Organization. World report on vision. Published 2019. Accessed February 2024. https:\/\/www.who.int\/docs\/default-source\/documents\/publications\/world-vision-report-accessible.pdf"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1002\/hec.1052"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1097\/00006982-200402000-00019"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0008-4182(00)80077-0"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2015.03.032"},{"issue":"7","key":"e_1_3_3_36_2","article-title":"Discontinuation, switching, and other long-term real-world treatment patterns among patients with diabetic macular edema initiating anti-VEGF: 6-year follow-up using the IRIS\u00ae Registry","volume":"63","author":"Kim E","year":"2022","unstructured":"Kim E, Garmo V, Tabano D, et al. Discontinuation, switching, and other long-term real-world treatment patterns among patients with diabetic macular edema initiating anti-VEGF: 6-year follow-up using the IRIS\u00ae Registry. Invest Ophthalmol Vis Sci. 2022;63(7):2523-F0249.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2019.10.019"},{"key":"e_1_3_3_38_2","unstructured":"US Bureau of Labor Statistics. Employment status of the civilian noninstitutional population by age sex and race. Published 2022. Accessed March 6 2025. https:\/\/www.bls.gov\/cps\/cpsaat03.pdf"},{"key":"e_1_3_3_39_2","unstructured":"Social Security Administration. Actuarial life table. 2022 (2025 TR). Accessed March 6 2025. https:\/\/www.ssa.gov\/oact\/STATS\/table4c6.html"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-60142-y"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1177\/24741264231156096"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40123-023-00750-9"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1111\/dme.14746"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2024.05.017"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2020.03.021"},{"key":"e_1_3_3_46_2","volume-title":"ASRS 2023 Preferences and Trends Membership Survey","author":"Hahn P","year":"2023","unstructured":"Hahn P, ed. ASRS 2023 Preferences and Trends Membership Survey. American Society of Retina Specialists; 2023."},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.1080\/20016689.2020.1717030"},{"key":"e_1_3_3_48_2","unstructured":"National Institute for Health and Care Excellence. Assessing cost effectiveness. The guidelines manual. Guidance| NICE. Published November 30 2012. Accessed January 21 2024. https:\/\/www.nice.org.uk\/process\/pmg6\/chapter\/assessing-cost-effectiveness"},{"key":"e_1_3_3_49_2","doi-asserted-by":"publisher","DOI":"10.1080\/09286586.2022.2072899"},{"key":"e_1_3_3_50_2","doi-asserted-by":"publisher","DOI":"10.3109\/09286586.2015.1066394"},{"key":"e_1_3_3_51_2","unstructured":"US Census Bureau. At height of pandemic more than half of people age 16 and over helped neighbors 23% formally volunteered. Census.gov. January 25 2023. Accessed January 21 2024. https:\/\/www.census.gov\/library\/stories\/2023\/01\/volunteering-and-civic-life-in-america.html"},{"key":"e_1_3_3_52_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2018.04.1828"},{"key":"e_1_3_3_53_2","unstructured":"US Bureau of Labor Statistics. Median usual weekly earnings of full-time wage and salary workers by age and sex. 2025. Accessed March 6 2025. https:\/\/www.bls.gov\/charts\/usual-weekly-earnings\/usual-weekly-earnings-current-quarter-by-age.htm"},{"key":"e_1_3_3_54_2","unstructured":"Does medicare cover refraction? Medicare & Medicare Advantage Info Help and Enrollment. September 30 2019. Accessed December 13 2023. https:\/\/www.medicare.org\/articles\/does-medicare-cover-refraction\/"},{"key":"e_1_3_3_55_2","unstructured":"Stepko B. Smart ways to save money on eyeglasses. AARP. 2021. Accessed December 13 2023. https:\/\/www.aarp.org\/health\/conditions-treatments\/info-2020\/save-money-on-glasses.html"},{"key":"e_1_3_3_56_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2006.07.054"},{"key":"e_1_3_3_57_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2013.2597"}],"container-title":["Journal of VitreoRetinal Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/24741264251359888","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/24741264251359888","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/24741264251359888","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T15:26:23Z","timestamp":1790695583000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/24741264251359888"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,11]]},"references-count":56,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["10.1177\/24741264251359888"],"URL":"https:\/\/doi.org\/10.1177\/24741264251359888","relation":{},"ISSN":["2474-1264","2474-1272"],"issn-type":[{"value":"2474-1264","type":"print"},{"value":"2474-1272","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,11]]}}}